Annotation Detail for PLCB2

Basic Information
Top
| Pathway ID | Pathway Name |
|---|
| PWY-6367 | D-myo-inositol-5-phosphate metabolism |
| LIPASYN-PWY | phospholipases |
| PWY-6351 | D-myo-inositol (1,4,5)-trisphosphate biosynthesis |
| Pathway ID | Pathway Name |
|---|
| Signaling by GPCR |
| Synaptic Transmission |
| Diabetes pathways |
| Opioid Signalling |
| Integration of energy metabolism |
| Pathway ID | Pathway Name |
|---|
| 200187 | Alpha-synuclein signaling |
| 200069 | Thromboxane A2 receptor signaling |
| 200071 | S1P1 pathway |
| 200190 | RAC1 signaling pathway |
| Pathway ID | Pathway Name |
|---|
| P04385 | Histamine H1 receptor mediated signaling pathway |
| P04391 | Oxytocin receptor mediated signaling pathway |
| P00019 | Endothelin signaling pathway |
| P04394 | Thyrotropin-releasing hormone receptor signaling pathway |
| P04374 | 5HT2 type receptor mediated signaling pathway |
| P05730 | Endogenous cannabinoid signaling |
| P00002 | Alpha adrenergic receptor signaling pathway |
| P05726 | 2-arachidonoylglycerol biosynthesis |
| P00027 | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway |
| P00031 | Inflammation mediated by chemokine and cytokine signaling pathway |
| P00057 | Wnt signaling pathway |
| Desease ID | Desease Name |
|---|
| 1934 | Cancer |
| Desease Name |
|---|
| Platelet PLC beta-2 deficiency |
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of PLCB2 mRNA | affects expression | 16483693
|
| C004742 |
daidzein |
daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein] | increases activity|increases reaction | 16972265
|
| C004742 |
daidzein |
daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK1 protein] | increases activity|increases reaction | 16972265
|
| C004742 |
daidzein |
daidzein promotes the reaction [GNB1 protein results in increased activity of PLCB2 protein results in increased activity of MAPK3 protein] | increases activity|increases reaction | 16972265
|
| D013749 |
Tetrachlorodibenzodioxin |
AHR protein affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PLCB2 mRNA] | affects reaction|increases expression | 16891777
|
| D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin results in increased expression of PLCB2 mRNA | increases expression | 16891777
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D000014 |
Abnormalities, Drug-Induced |
|
Tetrachlorodibenzodioxin |
3.59 | 14514962 11752688 15322242 |
| MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
4.30 | 18287403 |
| MESH:D000230 |
Adenocarcinoma |
|
daidzein |
3.50 | 11473722 |
| MESH:D018248 |
Adenoma, Liver Cell |
|
Tetrachlorodibenzodioxin |
4.12 | 16835633 |
| MESH:D000740 |
Anemia |
|
Tetrachlorodibenzodioxin |
3.39 | 11748828 |
| MESH:D001778 |
Blood Coagulation Disorders |
|
Tetrachlorodibenzodioxin |
3.53 | 12125929 |
| MESH:D001836 |
Body Weight Changes |
|
Tetrachlorodibenzodioxin |
4.66 | 15340226 |
| MESH:D001848 |
Bone Diseases, Developmental |
|
Tetrachlorodibenzodioxin |
3.02 | 15746008 |
| MESH:D001943 |
Breast Neoplasms |
|
Tetrachlorodibenzodioxin |
1.66 | 20435547 |
| MESH:D002277 |
Carcinoma |
|
Tetrachlorodibenzodioxin |
3.16 | 16835633 |
| MESH:D006332 |
Cardiomegaly |
|
Tetrachlorodibenzodioxin |
2.58 | 18670907 16120746 18850075 |
| MESH:D002318 |
Cardiovascular Diseases |
|
daidzein |
4.54 | 16332659 |
| MESH:D018281 |
Cholangiocarcinoma |
|
Tetrachlorodibenzodioxin |
3.58 | 16835633 |
| MESH:D002972 |
Cleft Palate |
|
Tetrachlorodibenzodioxin |
2.25 | 16354765 15340226 15668235 8697196 12621046 |
| MESH:D000013 |
Congenital Abnormalities |
|
Tetrachlorodibenzodioxin |
3.48 | 14669216 17141729 |
| MESH:D019465 |
Craniofacial Abnormalities |
|
Tetrachlorodibenzodioxin |
1.27 | 20055451 15322242 10048152 |
| MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
daidzein |
4.95 | 16647724 |
| MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Tetrachlorodibenzodioxin |
4.95 | 17107852 |
| MESH:D056486 |
Drug-Induced Liver Injury |
|
Tetrachlorodibenzodioxin |
1.62 | 20420201 |
| MESH:D004362 |
Drug Toxicity |
|
Tetrachlorodibenzodioxin |
3.09 | 11462148 |
| MESH:D004487 |
Edema |
|
Tetrachlorodibenzodioxin |
2.85 | 12711302 11000095 |
| MESH:D004489 |
Edema, Cardiac |
|
Tetrachlorodibenzodioxin |
4.77 | 18230668 16714409 15322242 |
| MESH:D016889 |
Endometrial Neoplasms |
|
daidzein |
4.57 | 11473722 |
| MESH:D004715 |
Endometriosis |
|
Tetrachlorodibenzodioxin |
3.47 | 10568697 9294722 |
| MESH:D007172 |
Erectile Dysfunction |
|
daidzein |
5.60 | 14972507 |
| MESH:D005124 |
Eye Abnormalities |
|
Tetrachlorodibenzodioxin |
3.34 | 11564622 |
| MESH:D005313 |
Fetal Death |
|
Tetrachlorodibenzodioxin |
4.11 | 11858732 |
| MESH:D005355 |
Fibrosis |
|
Tetrachlorodibenzodioxin |
3.60 | 20067830 |
| MESH:D006058 |
Gonadal Disorders |
|
Tetrachlorodibenzodioxin |
5.46 | 10696789 |
| MESH:D006330 |
Heart Defects, Congenital |
|
Tetrachlorodibenzodioxin |
2.53 | 10048152 11294989 |
| MESH:D006470 |
Hemorrhage |
|
Tetrachlorodibenzodioxin |
3.82 | 11000095 |
| MESH:D006529 |
Hepatomegaly |
|
Tetrachlorodibenzodioxin |
3.54 | 12621046 15340226 16120746 |
| MESH:D006869 |
Hydronephrosis |
|
Tetrachlorodibenzodioxin |
4.91 | 8697196 15340226 16959395 16354765 18606429 |
| MESH:D006973 |
Hypertension |
|
daidzein |
5.97 | 17169123 |
| MESH:D006973 |
Hypertension |
|
Tetrachlorodibenzodioxin |
5.97 | 18670907 18850075 |
| MESH:D007249 |
Inflammation |
|
Tetrachlorodibenzodioxin |
2.04 | 12200463 12878042 |
| MESH:D007569 |
Jaw Abnormalities |
|
Tetrachlorodibenzodioxin |
3.82 | 16580747 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tetrachlorodibenzodioxin |
1.25 | 12878042 |
| MESH:D008113 |
Liver Neoplasms |
|
Tetrachlorodibenzodioxin |
1.84 | 16984957 |
| MESH:D008114 |
Liver Neoplasms, Experimental |
|
Tetrachlorodibenzodioxin |
2.35 | 12151625 |
| MESH:D008175 |
Lung Neoplasms |
|
Tetrachlorodibenzodioxin |
1.24 | 19555203 11884234 |
| MESH:D017202 |
Myocardial Ischemia |
|
Tetrachlorodibenzodioxin |
3.38 | 12213967 |
| MESH:D009421 |
Nervous System Malformations |
|
Tetrachlorodibenzodioxin |
3.80 | 14600291 |
| MESH:D010382 |
Peliosis Hepatis |
|
Tetrachlorodibenzodioxin |
5.12 | 12520081 |
| MESH:D017119 |
Porphyria Cutanea Tarda |
|
Tetrachlorodibenzodioxin |
4.14 | 18163543 |
| MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Tetrachlorodibenzodioxin |
3.93 | 11896295 11222880 11118676 11399792 |
| MESH:D015619 |
Respiratory System Abnormalities |
|
Tetrachlorodibenzodioxin |
4.42 | 18990726 |
| MESH:D012878 |
Skin Neoplasms |
|
Tetrachlorodibenzodioxin |
2.21 | 16192470 |
| MESH:D013959 |
Thyroid Diseases |
|
Tetrachlorodibenzodioxin |
4.77 | 12697716 |
| MESH:D054079 |
Vascular Malformations |
|
Tetrachlorodibenzodioxin |
5.46 | 12125929 |
| MESH:D019282 |
Wasting Syndrome |
|
Tetrachlorodibenzodioxin |
5.12 | 15886252 |
PharmGKB Accession:PA33385
| Releated disease ID |
Related disease Name |
| PA445062 | Neoplasms |